Seladelpar clinical trials
Also written MBX-8025 and Livdelzi®.
How each study uses seladelpar is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the seladelpar studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Aug 2024 · LIVDELZI · NDA 217899 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 1
Gilead Sciences (14) · University of California, San Diego (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Hypolipidemic Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test seladelpar.
- Sep 2027Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).Phase 2 · University of California, San Diego
Studies
Open first, then newest update. How each study uses seladelpar is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingPhase 3Gilead SciencesNCT06051617Written as Seladelpar
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisRecruitingPhase 2Gilead SciencesNCT07841977Written as Seladelpar
- Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).Not yet recruitingPhase 2University of California, San DiegoNCT07305363Written as Seladelpar
- Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)CompletedPhase 3Gilead SciencesNCT06060665Written as Seladelpar 10 mg
- Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)Active, not recruitingPhase 3Gilead SciencesNCT03301506Written as Seladelpar 5 mg Capsule
- An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)CompletedPhase 1Gilead SciencesNCT04950764Written as Seladelpar
- Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)TerminatedPhase 2Gilead SciencesNCT02609048Written as Experimental: Seladelpar 50 mg
- A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSCTerminatedPhase 2Gilead SciencesNCT04024813Written as Seladelpar
- RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)CompletedPhase 3Gilead SciencesNCT04620733Written as Seladelpar 10 mg
- A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)TerminatedPhase 2Gilead SciencesNCT03551522Written as Seladelpar
- ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)CompletedPhase 3Gilead SciencesNCT03602560Written as seladelpar 10 mg
- Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)CompletedPhase 2Gilead SciencesNCT02955602Written as MBX-8025 2 mg Capsule
- Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsCompletedPhase 1Gilead SciencesNCT03369002Written as seladelpar
- Study to Evaluate the Effects of MBX-8025 in Patients With HoFHCompletedPhase 2Gilead SciencesNCT02472535Written as MBX-8025 50 mg (Dose Escalation Period 1)
- Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High CholesterolCompletedPhase 2Gilead SciencesNCT00701883Written as MBX-8025
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisOct 27, 2026NCT07841977
Codes
What other systems call seladelpar · ClinicalTrials.gg INT001553
- MeSH (NLM) C000713688seladelparConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7C00L34NB9SELADELPARConfirmed FDA, NLM, Wikidata
- Wikidata Q27268037seladelparConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167015SeladelparOne source FDA
- DrugBank DB12390One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000713688 | seladelpar | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7C00L34NB9 | SELADELPAR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27268037 | seladelpar | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167015 | Seladelpar | One source FDA |
| DrugBank | DB12390 | — | One source Wikidata |
Also registered as seladelpar lysine (UNII N1429130KR).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.